Phase 1 Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH (012410-2) in Patients With Survivin-Positive Malignant Gliomas.

Trial Profile

Phase 1 Study of Safety, Tolerability and Immunological Effects of SVN53-67/M57-KLH (012410-2) in Patients With Survivin-Positive Malignant Gliomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Mar 2017

At a glance

  • Drugs Survivin 2B peptide vaccine (Primary) ; Sargramostim
  • Indications Anaplastic astrocytoma; Astrocytoma; Brain cancer; Glioblastoma; Glioma; Gliosarcoma; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 24 Feb 2017 Status changed from active, no longer recruiting to completed.
    • 01 Nov 2016 Planned primary completion date changed from 1 Sep 2014 to 1 May 2017.
    • 01 Nov 2016 Status changed from completed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top